<SEC-DOCUMENT>0001213900-21-030986.txt : 20210604
<SEC-HEADER>0001213900-21-030986.hdr.sgml : 20210604
<ACCEPTANCE-DATETIME>20210604161616
ACCESSION NUMBER:		0001213900-21-030986
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20210604
DATE AS OF CHANGE:		20210604
EFFECTIVENESS DATE:		20210604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256799
		FILM NUMBER:		21996649

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>ea141958-s8_enlivextherap.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT><B>As
filed with the Securities and Exchange Commission on June 4, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5in; text-align: right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5in; text-align: right"></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES AND
EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B></B></FONT><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>FORM&nbsp;S-8</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Enlivex
Therapeutics Ltd.</B></FONT><B><FONT STYLE="font-size: 24pt"><BR>
</FONT></B>(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 50%; text-align: center"><FONT STYLE="background-color: white"><B>Israel</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 49%; text-align: center"><FONT STYLE="background-color: white"><B>Not Applicable</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center">(State or other jurisdiction of </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(I.R.S. Employer</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center">incorporation or organization)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Identification No.)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14 Einstein Street, Nes Ziona, Israel </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7403618</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(Zip Code)</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Enlivex Therapeutics Ltd. Global Share Incentive
Plan (2019)<BR>
</B>(Full title of the plan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COGENCY GLOBAL INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>122 East 42nd Street, 18th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10168</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: (212) 947-7200</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name and address for agent for service) (Telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Copy to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Drew M. Altman, Esq.</B><BR>
<B>Win Rutherfurd, Esq.</B><BR>
<B>Greenberg Traurig, P.A.</B><BR>
<B>333 S.E. 2nd Avenue, Suite 4400</B><BR>
<B>Miami, Florida 33131</B><BR>
<B>Tel: (305)&nbsp;579-0500</B></FONT></TD>
    <TD STYLE="width: 34%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Mr. Oren Hershkovitz</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Enlivex Therapeutics Ltd.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: +972.2.6208072</B></P></TD>
    <TD STYLE="width: 33%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Adrian&nbsp;Daniels,
    Adv.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Yigal Arnon &amp; Co.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>22 Rivlin Street</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Jerusalem 9424018,
    Israel</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Tel: (972) (2)
623-9220</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Indicate by check mark whether the registrant is
a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%">Large accelerated filer</TD>
    <TD STYLE="width: 42%">&#9744;</TD>
    <TD STYLE="width: 31%">Accelerated filer</TD>
    <TD STYLE="width: 2%">&#9746;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Non-accelerated filer</TD>
    <TD>&#9744;</TD>
    <TD>Smaller reporting company</TD>
    <TD>&#9744;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Emerging growth company</TD>
    <TD>&#9744;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">CALCULATION OF
REGISTRATION FEE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Title of securities to be registered</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount to be registered(1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed maximum offering price per share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed maximum aggregate offering price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of registration fee</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Ordinary shares, par value NIS 0.40 per share, to be issued under the Enlivex Therapeutics Ltd. Global Share Incentive Plan (2019)</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">4,150,704</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">9.26</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">(2)</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">38,435,519.04</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">4,193.32</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: left">Pursuant to Rule 416 of the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;), this Registration Statement shall also cover any additional ordinary shares, par value NIS 0.40 per
share (&ldquo;Ordinary Shares&rdquo;), of Enlivex Therapeutics Ltd. (the &ldquo;Registrant&rdquo;) which become issuable under the 2019
Global Share Incentive Plan (the &ldquo;2019 Plan&rdquo;) by reason of any stock dividend, stock split, recapitalization or other similar
transaction effected without the receipt of consideration which results in an increase in the number of the Registrant&rsquo;s outstanding
Ordinary Shares.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">The proposed maximum offering price per share has been estimated
in accordance with Rule 457(c) and 457(h)&nbsp;under the Securities Act solely for the purpose of calculating the registration fee. The
computation is based upon the average of the high and low prices of the Registrant&rsquo;s Ordinary Shares as reported on the Nasdaq
Capital Market on May 28, 2021.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>






<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">PART&nbsp;I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">INFORMATION REQUIRED IN THE SECTION&nbsp;10(a)&nbsp;PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information specified by Items 1 and 2 of Part
I of Form S-8 is omitted from this registration statement in accordance with the provisions of Rule 428 under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), and the introductory Note to Part I of Form S-8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The documents containing the information specified
in Part I of Form S-8 will be sent or given to participating employees as specified by Rule 428(b) under the Securities Act. Such documents
and the documents incorporated by reference herein pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that
meets the requirements of Section 10(a) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">PART&nbsp;II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 3.&nbsp; <U>Incorporation of Documents by Reference</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Enlivex Therapeutics Ltd. (the &ldquo;Registrant&rdquo;)
hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>The Registrant&rsquo;s Annual Report for the year ended December 31, 2020 on <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390021023865/f20f2020_enlivexthera.htm">Form 20-F</A> filed with the Commission on April 30, 2021;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>The Registrant&rsquo;s Reports on Form 6-K furnished to the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390021007761/ea135025-6k_enlivextherap.htm">February
                                                               9, 2021</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1596812/000121390021009072/ea135385-6k_enlivextherap.htm" STYLE="-sec-extract: exhibit">February 12, 2021</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1596812/000121390021029960/ea141839-6k_enlivextherap.htm" STYLE="-sec-extract: exhibit">May 28, 2021</A>; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>The Registrant&rsquo;s Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000114420414045171/v384900_8a12b.htm">Form&nbsp;8-A</A> filed with the Commission on July 28, 2014 (File No. 001-36578), in
which there is described the terms, rights and provisions applicable to the Registrant&rsquo;s Ordinary Shares, including any amendment
or report filed for purposes of updating such description, including the description of the Registrant&rsquo;s Ordinary Shares filed as
<A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/f20f2019ex2-1_enlivex.htm">Exhibit 2.1</A> to the Registrant&rsquo;s Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/f20f2019_enlivextherap.htm">Form 20-F</A> filed on April 30, 2020.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All documents or reports subsequently filed by the
Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the <FONT STYLE="background-color: white">Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;)</FONT>, and to the extent designated therein, certain reports on Form 6-K, furnished by the Registrant,
after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities
offered hereby have been sold or which deregisters all securities offered hereby then remaining unsold, shall be deemed to be incorporated
by reference in this Registration Statement and to be part hereof from the date of filing of such documents or reports. Any statement
in a document or report incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for
the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document
or report which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified
or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should rely only on the information provided
or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide
you with different information. You should not assume that the information in this Registration Statement or any related prospectus is
accurate as of any date other than the date on the front of the document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 4.&nbsp; <U>Description of Securities</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not required to be filed with this Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 5.&nbsp; <U>Interests of Named Experts and Counsel</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 6.&nbsp; <U>Indemnification of Directors and Officers</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli Companies Law, 1999, as amended,
or the Companies Law, a company may not exculpate an office holder from liability for a breach of a fiduciary duty. An Israeli company
may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result
of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended
and restated articles of association include such a provision. The company may not exculpate in advance a director from liability arising
due to the breach of his or her duty or care in the event of a prohibited dividend or distribution to shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law and the Israeli Securities
Law, 5728-1968, or the Securities Law, a company may indemnify an office holder in respect of the following liabilities, payments and
expenses incurred for acts performed by him as an office holder, either in advance of an event or following an event, provided its articles
of association include a provision authorizing such indemnification:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator&rsquo;s decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&rsquo;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">reasonable litigation expenses, including reasonable attorneys&rsquo; fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding; (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">a monetary liability imposed on the office holder in favor of all the injured parties by the breach in an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Securities Law;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&rsquo; fees; </TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">reasonable litigation expenses, including attorneys&rsquo; fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was convicted of an offense that does not require proof of criminal intent;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">expenses incurred by the office holder in connection
    with a proceeding under Chapter G'1, of the Restrictive Trade Practices Law 5748-1988 (the &ldquo;Restrictive Trade Law&rdquo;), including
    reasonable litigation expenses, including attorney's fees; and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Any other obligation or expense in respect of
    which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters
    referenced in Section 56H(b)(1) of the Securities Law.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An &ldquo;Administrative Procedure&rdquo; is defined
as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures
of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions)
to the Securities Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law and the Securities Law,
a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder
if and to the extent provided in the company&rsquo;s articles of association:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">a monetary liability imposed on the office holder in favor of a third party;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">a monetary liability imposed on the office holder
    in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities Law;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">expenses incurred by the Office Holder in connection
    with a proceeding under Chapter G'1, of the Restrictive Trade Law, including reasonable litigation expenses, including attorney's fees;
    and</P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys&rsquo; fees.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law, a company may not indemnify,
exculpate or insure an office holder against any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">an act or omission committed with intent to derive illegal personal benefit; or</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#9679;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify">a fine or forfeit levied against the office holder.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law, exculpation, indemnification
and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with
respect to, the chief executive officer, directors or controlling shareholders, their relatives and third parties in which controlling
shareholders have a personal interest, also by the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Amended and Restated Articles of Association
permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. Our office
holders are currently covered by a directors&rsquo; and officers&rsquo; liability insurance policy. As of the date of this registration
statement, no claims for directors&rsquo; and officers&rsquo; liability insurance have been filed under this policy and we are not aware
of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which indemnification
is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into agreements with each of our
directors and Professor Mevorach, exculpating them, to the fullest extent permitted by the Companies Law, from liability for monetary
or other damages due to, or arising or resulting from, a breach of the duty of care to the Registrant and undertaking to indemnify them
to the fullest extent permitted by Israeli law, including with respect to liabilities resulting from certain acts performed by such office
holders in their capacity as an office holder of the Registrant, our subsidiaries or affiliate, subject to limited exceptions, and undertaking
to indemnify them to the fullest extent permitted by law, subject to limited exceptions, including, with respect to liabilities resulting
from this offering, to the extent that these liabilities are not covered by insurance. The indemnification is limited both in terms of
amount and coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 7.&nbsp; <U>Exemption from Registration Claimed</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 8.&nbsp; <U>Exhibits</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following are the exhibits required by Item
601 of Regulation S-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 9%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Exhibit</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; font-size: 10pt"><B>Description</B></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">1.1</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000114420419016097/tv516517_ex99-2.htm">Amended and Restated Articles of Association of Enlivex Therapeutics Ltd., filed as Exhibit 99.2 to Form 6-K filed on March 27, 2019 and incorporated herein by reference.</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">5.1</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="ea141958ex5-1_enlivextherap.htm">Opinion of Yigal Arnon &amp; Co.</A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">23.1</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="ea141958ex5-1_enlivextherap.htm">Consent of Yigal Arnon &amp; Co. (included as part of Exhibit 5.1).</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">23.2</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="ea141958ex23-2_enlivextherap.htm">Consent of Yarel + Partners.</A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">24.1</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="#sig_001">Power of Attorney (included on signature page)</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">99.1</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/f20f2019ex4-3_enlivex.htm">Enlivex Therapeutics Ltd. Global Share Incentive Plan (2019), filed as Exhibit 4.3 to Form 20-F filed on April 30, 2020 (File No. 001-36578), and incorporated herein by reference.</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 9.&nbsp; <U>Undertakings</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;The
undersigned Registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1)&nbsp;To
file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)&nbsp;To
include any prospectus required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)&nbsp;To
reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration
Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes
in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii)&nbsp;To
include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any
material change to such information in the Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>provided</U>,&nbsp;<U>however</U>, that paragraphs
(a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs
is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of
the Exchange Act that are incorporated by reference in the Registration Statement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2)&nbsp;That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3)&nbsp;To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;The
undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the
Registrant&rsquo;s annual report pursuant to Section 13(a)&nbsp;or Section 15(d)&nbsp;of the Exchange Act (and, where applicable, each
filing of an employee benefit plan&rsquo;s annual report pursuant to section 15(d)&nbsp;of the Exchange Act) that is incorporated by reference
in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a
claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director,
officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="sig_001"></A>SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&nbsp;S-8,
and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Nes-Ziona, State of Israel, on June 4, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="text-transform: uppercase; background-color: white">Enlivex Therapeutics Ltd.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Oren Hershkovitz</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 31%">Oren Hershkovitz</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">POWER OF ATTORNEY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">KNOW ALL MEN BY THESE PRESENTS, that each person
whose signature appears below constitutes and appoints Shai Novik, Oren Hershkovitz and Shachar Shlosberger, and each of them, with full
power to act without the other, such person&rsquo;s true and lawful attorneys-in-fact and agents, with full power of substitution and
resubstitution, for him and in his name, place and stead, in any and all capacities, to sign this Registration Statement, and any and
all amendments thereto (including post-effective amendments), and to file the same, with exhibits and schedules thereto, and other documents
in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them,
full power and authority to do and perform each and every act and thing necessary or desirable to be done in and about the premises, as
fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Oren Hershkovitz</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">Chief Executive Officer and Director</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">June 4, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Oren Hershkovitz</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(<I>Principal Executive Officer)</I></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Shachar Shlosberger</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">Chief Financial Officer</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">June 4, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Shachar Shlosberger</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(<I>Principal&nbsp;Financial&nbsp;and&nbsp;Accounting&nbsp;Officer</I>)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Shai Novik</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">Chairman and Director</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">June 4, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Shai Novik</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Brian Schwartz</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">Director</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">June 4, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Brian Schwartz, M.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Sangwoo Lee</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">Director</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">June 4, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Sangwoo Lee</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Abraham Havron</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">Director</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">June 4, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Abraham Havron, Ph.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Bernhard Kirschbaum</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">Director</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">June 4, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Bernhard Kirschbaum, Ph.D</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Michael Habib</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">Director</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">June 4, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Michel Habib</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Gili Hart</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">Director</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">June 4, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Gili Hart, Ph.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">/s/ Baruch Halpert</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">Director</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">June 4, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Baruch Halpert</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Signature of Authorized U.S. Representative
of Registrant</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933, as amended,
the undersigned, the duly authorized representative in the United States of Enlivex Therapeutics Ltd., has signed this Registration Statement
on June 4, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; font-size: 10pt; width: 35%">/s/ Colleen A. De Vries</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">Name:&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">Colleen A. De Vries</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">Title:</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">Sr. Vice President on behalf of&nbsp;COGENCY GLOBAL, INC.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-6</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea141958ex5-1_enlivextherap.htm
<DESCRIPTION>OPINION OF YIGAL ARNON & CO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-align: left"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; width: 16%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Yigal Arnon (1929-2014)</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dror Vigdor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amalia Meshi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amnon Lorch</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hagai Shmueli</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Barry Levenfeld</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David H. Schapiro</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hagit Bavly</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Orna Sasson</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Barak Tal</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shiri Shaham</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Doron Tamir</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Daniel Abarbanel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Osborne</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gil Oren</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ronit Amir Yaniv</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Orly Tsioni</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mordehai Baicz</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Barak Platt</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Benjamin Horef</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yoran Gill</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Asaf Eylon</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Daniel Marcovici</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adrian Daniels</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yuval Shalheveth</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jacob Ben Chitrit</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Peter Sugarman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ben Sandler</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boaz Fiel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joeri Kreisberg</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Simon Weintraub</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ruth Loven</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yarom Romem</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adam Spruch</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yuval Bargil</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eliran Furman<BR>
    Eran Lempert</P></TD>
    <TD STYLE="padding-right: 2pt; width: 16%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ofir Levy<BR>
    Daniel Green</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hanital Belinson</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yoheved Novogroder<BR>
    Oren Roth<BR>
    Dror Varsano</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Odelia Sidi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shira Lahat</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Micki Shapira</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eran Zach</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ido Chitman&#9;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aner Hefetz</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Akrish</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nir Rosner</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assaf Mesica</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Liron Hacohen</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guy Fuhrer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ezra Gross</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Roness</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eli Greenbaum</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lee Maor<BR>
    Nimrod Vromen</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guy Sagiv</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shani Rapoport</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lior Gelbard</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Keren Tal</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Naftali Nir</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yael Hoefler</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sagi Schiff</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Netanella Treistman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Daniel Damboritz</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yulia Lazbin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joshua Lieberman<BR>
    Eyal Aichel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Roy Masuri<BR>
    Avi Anouchi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sivan Gilron Dotan</P></TD>
    <TD STYLE="padding-right: 2pt; width: 16%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tomer Bar-Nathan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Edan Regev</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gitit Ramot-Adler</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guy Kortany</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Goor Koren<BR>
    Roey Sasson</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nir Rodnizky</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michal Sagmon</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hila Rot<BR>
    Eran Kadosh</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neta Goshen</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chen Lanir</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Daphna Livneh</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tamar Gilboa<BR>
    Adi Samuel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alona Toledano<BR>
    Yuval Shamir</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lihi Katzenelson<BR>
    Inbar Hakimian-Nahari</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Naama Hod<BR>
    Shahar Uziely</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yehudit Biton</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Omri Schnaider</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rinat Michael</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adi Attar</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amos Oseasohn</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ofir Paz</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adi Daniel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dafna Shaham</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Miriam Friedmann</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Roni Osborne</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shir Eshkol</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Noam Shochat<BR>
    Noa Slavin<BR>
    Michael Horowitz</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guy Fatal<BR>
    Shani Lorch</P></TD>
    <TD STYLE="padding-right: 2pt; width: 16%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Itamar Cohen<BR>
    Shai Margalit</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yonatan Whitefield</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moshe Lankry<BR>
    Nir Kamhi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shira Teger</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rachel Lerman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ravid Saar</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sophie Blackston</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elad Morgenstern<BR>
    Ron Ashkenazi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sara Haber</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carmel Nudler</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shmuel Brill</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 0">Ben Nachshon</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yehonatan Cohen</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Shmulevitz</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tair Cherbakovsky</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aaron Shaw<BR>
    Ophir Dagan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guy Ziv-Shalom</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lior Cohen Goldstein Shiri Vilkin<BR>
    Liad Kalderon</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nataly Damary</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shiran Glitman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dani Weissberg</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lareine Khoury</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nohar Hadar</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nitzan Kahana</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tali Har-Oz</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tal Alon</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ohad Sarusi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mor Ido<BR>
    Nechemia Englman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tomer Tako<BR>
    Natalie Korenfeld</P></TD>
    <TD STYLE="padding-right: 2pt; width: 18%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moshe Pasker</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mazi Ohayon</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nitzan Fisher-Conforti</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Victoria Savu</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Derora Tropp</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hila Amiel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chaim Cohen</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michal Mor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Daniel Siso</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shalhevet Hetli</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Galit Frank</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maytal Spivak</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avraham Schoen</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elan Loshinsky</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Josh Hauser</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eitan Cohen</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Itai Guttel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dror Kanarik Sarig</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Royi Heilig</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carmel Bareket<BR>
    Maor Alev</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vered Glaubach</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yair Taitelbaum</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gabi Priel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regina Pevzner<BR>
    Sophy Litvin</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Igal Lavi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carmel Bareket<BR>
    Maor Layani</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Areen Nashef<BR>
    David Chesterman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ido Zahavi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guy Yarom</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hillel Segal<BR>
    Inbar Rosenthal<BR>
    Hadar Stein</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avital Salzman</P></TD>
    <TD STYLE="text-align: left; padding-right: 2pt; width: 18%; padding-left: 2pt">
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rotem Cohen</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Idan Adar</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shahar Iluz</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Itay Ashkenazi</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Roei Brizel</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ido Sella</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Evyatar Latz</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hadil Nassif Khawand<BR>
    Maayan Malka Rublin</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ran Aziel</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stav Orenstein</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avia Ickovics</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Danielle Gabrieli</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lior Hochshtadt</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ofek Sinai</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shmuel Ofen</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Or Perel</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Katya Kagantsov</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Uri Galatt</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yarden Weber</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maya Haran<BR>
    Avishai Oberman<BR>
    Elior Goldenberg<BR>
    Eyal Safrai</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yuval Dekel<BR>
    Adina Mirchin</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Gidon
    Weinstock Of Counsel</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Roy Keidar Of Counsel</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tamar
    Tavory Of Counsel</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Paul H. Baris (1934-2010)</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rami Kook</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nira Kuritzky</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eran Ilan</P></TD></TR>
  </TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-align: center">Tel Aviv | June 4, 2021</P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">Enlivex Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">14 Einstein Street,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">Nes Ziona, 7403618</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">Israel</P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">Dear Sir/Madam:</P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">We have acted as Israeli counsel for Enlivex Therapeutics
Ltd., a company organized under the laws of the State of Israel (the &ldquo;Company&rdquo;), in connection with the registration statement
on Form S-8 (the &ldquo;Registration Statement&rdquo;) filed with the Securities and Exchange Commission under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), for the purpose of registering under the Securities Act 4,150,704 ordinary shares of the
Company, par value NIS 0.40 per share (the &ldquo;Ordinary Shares&rdquo;), that may be issued pursuant to equity-based awards granted
under the Company&rsquo;s Global Share Incentive Plan (2019) (the &ldquo;Plan&rdquo;). The Ordinary Shares issuable under the Plan are
referred to herein as the &ldquo;Award Shares.&rdquo;</P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">In rendering an opinion on the matters hereinafter set
forth, we have assumed the authenticity of all original documents submitted to us as certified, conformed or photographic copies thereof,
the genuineness of all signatures and the due authenticity of all persons executing such documents. We have assumed the same to have been
properly given and to be accurate, we have assumed the truth of all facts communicated to us by the Company, and we have also assumed
that all consents, minutes and protocols of meetings of the Company&rsquo;s board of directors and shareholders meetings of the Company
which have been provided to us are true, accurate and have been properly prepared in accordance with the Company&rsquo;s incorporation
documents and all applicable laws. In addition, we have assumed that in connection with the issuance of Ordinary Shares under the Plan,
the Company will either (i) receive consideration in an amount not less than the aggregate par value of the Award Shares covered by each
such issuance, or (ii) otherwise act as required pursuant to the Israeli Companies Law 5799-1999 to record on the Company&rsquo;s balance
sheet under shareholder&rsquo;s equity, the aggregate par value of the Award Shares covered by each such issuance.</P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font-size: 10pt"><IMG SRC="ex5-1_002.jpg" ALT="" ></TD>
    <TD STYLE="text-align: left; width: 98%; vertical-align: middle">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1 Azrieli Center, Tel Aviv, 6702101 | Phone: +972-3-6087777 | Fax:
    +972-3-6087724</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">31 Hillel Street, Jerusalem, 9458131 | Phone: +972-2-6239239 | Fax:
    +972-2-6239233</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.arnon.co.il | info@arnon.co.il</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">On the basis of such investigation as we have deemed necessary,
and subject to the assumptions set forth above, we are of the opinion that the Award Shares have been duly and validly authorized for
issuance and, when issued upon due exercise in accordance with the applicable award agreement and pursuant to the terms of the Plan, the
Awards Shares will be legally and validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">We hereby consent to the filing of this opinion as an exhibit
to the Registration Statement. In giving this consent, we do not thereby admit that we come within the category of persons whose consent
is required under Section 7 of the Securities Act, or the rules and regulations of the Securities and Exchange Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">The above opinion is based on facts existing on the date
hereof and of which we are aware. We express no opinion as to any laws other than the laws of the State of Israel as the same are in force
on the date hereof and we have not, for purpose of giving this opinion, made any investigation of the laws of any other jurisdiction.
This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">This opinion letter is rendered as of the date hereof and
we disclaim any obligation to advise you of facts, circumstances, events or developments that may be brought to our attention after the
effective date of the Registration Statement that may alter, affect or modify the opinions expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Yigal Arnon &amp; Co.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Yigal Arnon &amp; Co.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font-size: 10pt"><IMG SRC="ex5-1_002.jpg" ALT="" ></TD>
    <TD STYLE="text-align: left; width: 98%; vertical-align: middle">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1 Azrieli Center, Tel Aviv, 6702101 | Phone: +972-3-6087777 | Fax:
    +972-3-6087724</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">31 Hillel Street, Jerusalem, 9458131 | Phone: +972-2-6239239 | Fax:
    +972-2-6239233</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.arnon.co.il | info@arnon.co.il</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-indent: 1in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.05pt 0pt 0; text-indent: 1in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>ea141958ex23-2_enlivextherap.htm
<DESCRIPTION>CONSENT OF YAREL + PARTNERS.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 78px; width: 163px"></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 83px; width: 266px"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference in this
Registration Statement on Form&nbsp;S-8&nbsp;of Enlivex Therapeutics Ltd. of our report dated April 20, 2021 with respect to the financial
statements of Enlivex Therapeutics Ltd. included in its Annual Report on Form 20-F for the year ended December 31, 2020, filed with the
Securities and Exchange Commission on April 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ Yarel + Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Yarel + Partners</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">June 4, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>
<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !+ 7(# 2(  A$! Q$!_\0
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MU"[FTFTE^,L_PR^-%SJNKW>='\+_ !$^*'A_2HK;2=+/E_VJ5_-#_P %8?\
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M]I]]_'GX_P#_  5O_8J\!ZG^T/\ %GP-^QS^V!\"/A_I-UXF^-_@O]G3PO\
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M?9U<7A<=@,3A:T\)5MBJ$ZF$P^)J?T/_ /!*O_@IW\.O^"F7P'N_%^E6.G^
M_CI\.I;/P_\ '/X1"_EU ^$?$%V+V/2/$NA27*VVH:CX \9#3-0NO#]Y<QI>
M:??:?KOA/4YYM7\.7MW<^6>$_P!J/_@I5J?[?^O_ +$OB#P1^QG9Z'X1^!_@
M_P#:-UCXR:9)\99EUCX<>*_'.I?#^ST71_ EQK8N=/\ '%UXC\,^+[5(-0\2
M7.A6&F:+%K<VIWLU_:Z#+^8_[7W['OQG_9*\-?LV_P#!9[_@GI8R6OQ>\ _L
M_?"VY_;-^#EHEU-X;^/'PE7X>^#Y?%OB_4=%LT>6YN(](T>U;XI6MI#-<W-K
MHGAOXQ>'$TKXB_#O4-0\9_<G_!/[]L;X/_MX?\%%/&_[1_P5U0W'ASQ5_P $
MQOV:=/\ $7AN]EA/B3X<^/-*_::_:?;Q1\//&%M"2EKX@\/RWMK,DT6_3M>T
M+4=$\5Z#<W_AS7](U"[RI8S$RG@\#BZU6CC8U\,W4HM4Z>8X&K2K2]O%.G-*
M<90IT\53@XSHU5*4;4J\7'T\RX8R'#X;BGB[AC*L!FG"6(RC/:<<'FE"KCL;
MP)Q=EV.R[#_V1B:D,;AV\-6I8G&XWA_&XE5L-FV73HT:J_M'**M.K^^%?R.?
MLM_M"Z1_P2U_X*M_\%9/@W\>_ OQ:\;^)_VO?B%H'[3'[,6A_![X;Z[\1?'W
MQO@\3>,_BYXSM/A]X#TFPM[==1OX;;XG:KH%IJ?B#5_#G@3PS??"+XE#7/$^
MEVUH+I_Z/_VWOCEK_P"S-^QY^T[^T'X3TNTUGQ7\'/@9\3/B%X6TW4;>:[TJ
MY\2^&O">IZCH']M6UM<V=S-H4.KPV=QKB6]W;7!TF*]\FXAEV2+_ #(_L[_\
M$G/$?[8O_!-CX:_MY^"_C+XOG_X*Q_$7QM>_M>^$/VHM?\73W5]J7C#P]KNL
M:3X,^"FH).)= \/> D\+Z%HFFQ6L.E-;>#_'-NJ"WD^&-E=?#.?7-YUY8K!0
MP5-SQN#AB,Q5^1Q>&Y?J56E"$VE5Q%;VC^KP<H0C.BG4J*-11EYOACALGH</
M<68OBW&1P?"G$^(R;@:3@L3&O'/EB%Q9EF88G%853JY=D>62R^']M8BG0Q>+
MK87,YPP&$E6P4ZU+]@_V"_V.?CXG[7O[2W_!33]KS2?#_P ,?CC^T?X/\-_"
M?X>?LW^#?$%GXPT_X$_ WPN/#$EKI7Q \=Z?YFC^-OBGXDOO!GAO4M>F\*RS
M>%-"NK76)=(U74;7Q/;Z!X)_82_OK32[&]U/4)X[6PTZTN;Z]NI21%;6EI"]
MQ<SR$ D1PPQO(Y )"J< GBOXY?A_\0?@M_P4V^.7[&/PS\:>&OC=^S-^W5IG
M[47Q%\/_ /!2#X&^!_B_\;_AQ8:KX1^%'P5^(WCCQ=XA;0-&\<16>C?#_P")
M/Q.\/_#SPY:ZAI4FF^+?!5[XGUSP/:^)M2@N?#?CGQ)_6OX2^#W@#P%\,C\(
M/!FCSZ#X#73-?TF#2QJ^LZO=06_B:?4;O6)/[8\0:AJVL7-S=7FJWUUY][?W
M,B23;4*Q)'&O1E-:%6E66&@I4(U)5/K$Z[G5Q&)Q$?K%:5:G["DZ-6,Y*GB*
M;4?8U(^QA34::;\;Q*RS%8',LLJ9]BJE+-ZN!PN"CDF&RF&$R[)N'\EJ?V-E
M=/*\?'-\RIYGEU?"4I8O)L=2=;^U,%B'F>)Q<L3C*M.G_+C_ ,$&KO4/^"AG
M[<'[<7_!5?XU6[Z[XHTC7-%^$?[.FGZJ\5]:_"3PAXHL-<U.\T#PY;20B#2+
M[PS\+7\"^$[?5]*6SN-3?QE\5-2U%9;_ ,=:[<7W];E?R3?\&SUQJ_[-/Q._
MX*$?\$X_BP%T#XQ?![XF:)X_MM"NO/BG\2:3I%JGPM\8^*-$AFBB%QX=2VTK
MX2>(=-U8*D6L:#\2O#&I68EL[E)%_K9J.'M<KI3E=XBI6Q4\8Y?Q'C'B:JQ'
MM.O/&48PL_AA&$4E!1.OQQ2I^(N9X7#*$<DP66<.X7A:G0=\'#A>.0995R>6
M!M^[>&KTZV)Q,JE.ZK8JMBJU64\1/$-?EMX!_80M?A!_P5B^)?[:GPX\*:9H
MOP^_:(_9-UCPA\79=+N=+LHD_: T#XJ?#:_T_P 0RZ$;N&_DN_B3X LI)M3U
M#1]+ETPZY\/]7UGQ+>0>(O%\$VM^3_$K_@I%\</C?^UE\0OV'/\ @FA\+_AC
M\2_B1\"O*;]IK]I7X^ZKXIM?V:_@/J1O;BP7P -$^'C0^-OB=\2KV_T[7=#7
M0=)UWPK::9XD\/ZWIEQ?7MMX<\=:CX*^O(_VP['Q!_P4&UO]A;P:/#NHZGX%
M_9+U?]H#XD:R;B:[U+PSXMUWXC^"/"7PR\'3):79MM.:X\,ZEXD\7^(]/U"Q
MEU2;2]8\ :CI\EG87LPU3\1O^#5S[#:?L_\ [:FB>+8YX/VAM+_:XO?^%R6^
MM%_^$OA@?P#X9L=(7Q&MR/MZ2K\0M,^,<4@O2TW]O1>)"Y\\S@9SJ0CBL-E^
M"J.A2QF-S.KBZU+EC.-7#0P]7$8?#R<)1ISK5JL93J1A*<$J_LTIR<X=F%P&
M)Q'#N><:<68&GF^8<+\*^'^7<.99CG7J8>ME^?8O.\NR;/,\HPQ-#$8S"Y;E
MN7UZ6'PD\1A\/B:U;)GC*DL+3I4,5]K_ +0G[7?_  4Q_P"">7AU/CW^U5\.
MOV9_VK_V3=$OM"L_BYXB_9-\,_$KX0?';X-Z7K&IPZ;<>/G^'_Q4^(_Q+\(_
M$GPAI=S<V5E/8Z9XM\(ZM;W5_%J.KWFD^'+;5-9TS]A/A-\5_AW\=/AGX&^,
M7PE\5:;XW^&OQ)\-:7XN\%^*M*^T)9ZSH6L6R7-I<&VO8+74-.O(@S6VI:1J
MMG8ZQHVI07>DZQ86.IV=W:0^,?MUW7@^R_8D_;"N?B$T \"1_LO?'P>,%N<&
M*7PW)\*_%46LVY4D&5[FP>>WBA3,D\LJ0Q!I'13^5/\ P;-6_CN#_@E+\.F\
M7O>-H=S\6_C?<?#1+IRT4?@P^.;N'5A8(<>59R_%"'XC7)4?+)>3W=PN5G!/
M13J5<-FD,"ZU7$4,3@ZV*A[:7M*V'J8>M3IR7M>2$I4*T:JY8U%*5.K!J$W"
M3C'PL7E^79YX=XOB]9=@,GSC(N*\LX>Q']ET98++L\P.=97CL?0F\O>(Q-##
MYKE5;+ZGMJV"G2I8S+L7">*PM/$8>G7K?T 4445ZY^:'SO\  C]EKX.?L\7'
MC;7O N@3ZA\1OBCK<GB3XM?&3QE=CQ1\7_BKKK.[6]UXY\=WL*ZGJ&F:+"_]
MG>$O"-@-,\$>!=%C@\/^!_#/AW0K>#3H_P \?VL/B%XS_9O_ &_OA+XH_9*^
M'UG^T-\?_P!IKX3:IX'_ &A?V3]%\5:?X$N;[X:_#6;5]2^"O[8_CWQW/X?U
MO0_A?X;^%WBR^\5_ O6?%?C.&2^^*.C?$G1/"G@/3/&7BCX1Z/X8B\ _X*9^
M,?%G_!-CX<W7Q$_92_:Q_:3N/C[\2/&/AX?"#]C'QYJUE^U7\,_B3=ZOX_\
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MPZ\"2?%.TT27PS:?$M_"/A]_B!:^&YV#S>'[?QDVGGQ%!HDS@/+I46I+82,
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M?/VL[_PQI^FZGX?O]&G/PX\:'X$V7[3^H> M3+Q:G\/OBU^SM)?PZQHNL:U
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M&TR?!;Q5&YV@A6RA(^<,!G(P>:^HJQI?Q,1YU8?^F*2/6S!WP61+MEN)3_\
M#SF+_)A1116QY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !. *,# 2(  A$! Q$!_\0
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ME:)=SA257U-4&N[U-"2>.W_TH@9C/;GF@#5HK,LKV]ETEYIK?%RF<1]-U5]
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M0YXK.NM8DTR^M(+Y%,=VWEHZ?PMZ&HK[Q!)IFK&*[MC]A('^DISL)_O#T]Z
MY6<)JGPX\2:IXK77WO;1+E'5D0 X '05Z7IC7[6__$R2)91_SS/!HLKQ[J:<
M80Q(1L93G<#5*X\11V^NV]BR?N9LJ)\\!Q_#0%F<EXP^&4^J>(X=;T"[6QO
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@W<2!AU8CUJW!;2QW#2RSM(",!>@%6:6@+L****!'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !3 0H# 2(  A$! Q$!_\0
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MG697U/77F\33V=U:SE;:U R& '  [YKI+B'5-=\&6VI7%[<Z9>1VQE=(N-Q
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H@ HHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
